Songmao Zheng

Understand the implications of ILD toxicity monitoring in Antibody Drug Conjugate (#ADC\) trials and how to meet worldwide #regulatory expectations in this on-demand webinar. https://lnkd.in/gbb2jdtC #MedicalImaging #Oncology #ChooseCalyx

1

Join us at #ACSDenver to interact with international chemists! 𝗘𝗻𝗴𝗮𝗴𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗔𝗖𝗦: 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗘𝘆𝗲𝘀 𝗼𝗳 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝘀 Want a new perspective on engagement in the ACS? Catch our presenters at this poster session!

4

Understand the implications of ILD toxicity monitoring in Antibody Drug Conjugate (#ADC\) trials and how to meet worldwide #regulatory expectations in this on-demand webinar. https://lnkd.in/gaHgEhE9 #MedicalImaging #Oncology #ChooseCalyx

1

Malte Lenders and colleagues conclude that the pharmacokinetic profile of pegunigalsidase alfa depends on the presence of neutralizing anti-AGAL antibodies, which result in reduced plasma half-life and peak enzyme activity after infusion. #pegunigalsidase #FabryDisease #Pharmacokinetics #openaccess https://lnkd.in/gt8CCkFS

3

Understand the implications of ILD toxicity monitoring in Antibody Drug Conjugate (#ADC\) trials and how to meet worldwide #regulatory expectations in this on-demand webinar. https://lnkd.in/gsFnCN8p #MedicalImaging #Oncology #ChooseCalyx

1

Register today for "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar will feature two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. To learn more, visit the registration page and save your spot today. Register here: https://lnkd.in/eVKhuZYm

17

Register today for "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar will feature two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. To learn more, visit the registration page and save your spot today. Register here: https://lnkd.in/eVKhuZYm

27

1 Comment

Here is our colorful paper. We introduced a novel data acquisition and processing method, CHARDA, to help perform structural analysis of biopolymers with MS and MS/MS. The color coding of the ionic charge states resulting from CHARDA provides a third dimension to mass spectra, facilitating the analysis of crowded MS and MS/MS data. The simplified CHARDA can be implemented in real time, online with data acquisition on most FTMS instruments. https://lnkd.in/ecdKVF4s

70

👉 Check out a new peer-reviewed paper published in the journal #JPBI (Journal of Pharmaceutical and BioTech Industry): https://lnkd.in/g4YQPxjh 🌱 #openaccess #indomethacin; #co_crystallization; #XRD; #THz; #solubility

2

Please join the IMAG/MSM WG on Multiscale Modeling and Viral Pandemics and GLIMPRINT, Thursday, December 12th at 3 pm Eastern Standard Time (EST) for: Digital Twin Approaches in Quantitative Systems Pharmacology Valeriu Damian, Senior Director System Modelling and Translational Biology at GSK Originally developed in the manufacturing industry, digital twin concepts have emerged as a transformative tool in quantitative systems pharmacology (QSP). This talk explores how digital twins can estimate population responses in clinical trials and enable personalized treatments, particularly for rare diseases and severe conditions where large-scale trials are impractical. We will compare digital twin methodologies with traditional virtual population algorithms in QSP modeling, highlighting how these approaches integrate patient-specific clinical data, and treatment history to build individualized models. Using a pediatric bone marrow transplant model as an example, we will discuss the challenges of balancing model accuracy with timely utility, emphasizing the importance of actionable predictions within the clinical decision-making window. For more information see: https://lnkd.in/gvhXgW7H Register at: https://lnkd.in/grPyacr5 #networks, #cellcycle, #embryogenesis,, #mathematicalbiology, #computationalbiology, #signaling, #QSP, #Pharmacology, #DrugDiscovery, #Pharma, #DigitalTwins, #ClinicalTrials, #Pediatrics, #Transplants, #BoneMarrow, #Immunology, #Clinical, #Medicine, #Translational, #IMAGMSM, #MathematicalBiology, #SystemsBiology,#Biology, #MSMViral, #IUB, #Glimprint, #Biocomplexity, #Methodologies, #Biotechnology, #GSK, #GlaxoSmithKline

10

In a recently published Perspective, Catherine Hutchings and Aaron Sato discuss phage display technology and its impact in the discovery of novel protein-based drugs. From the abstract: Areas covered In this perspective, the authors summarize the application of phage display for drug discovery and provide examples of protein-based drugs that have either been approved or are being developed in the clinic. The amenability of phage display to generate functional protein molecules to challenging targets and recent developments of strategies and techniques designed to harness the power of sampling diverse repertoires are highlighted. Expert opinion Phage display is now routinely combined with cutting-edge technologies to deep-mine antibody-based repertoires, peptide, or alternative scaffold libraries generating a wealth of data that can be leveraged, e.g. via artificial intelligence, to enable the potential for clinical success in the discovery and development of protein-based therapeutics. https://lnkd.in/ekeA5Z4j

9

Cellino Biotech is automating the production of high-quality induced pluripotent stem cells (#IPSC), a breakthrough that could make personalized, regenerative treatments more accessible and efficient. I met with Nabiha Saklayen, Ph.D. to discuss how #machinelearning, #laseroptics, and #stemcell biology can pave the way for stem cell-derived #regenerativemedicine. https://lnkd.in/eazrpUDG

37

Drug: Target in Focus: PRMT1 belongs to the class I-like SAM-binding methyltransferase superfamily. AZ-PRMT5i-1 is an orally bioavailable MTA-cooperative PRMT5 inhibitor that specifically targets MTAP-deleted cancers. Targeting PRMT5 in MTAP-deleted cancers has become highly competitive. Initially, PRMT5 was dismissed due to intolerable toxicities from first-generation inhibitors. Developed by AstraZeneca. @AstraZeneca #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements

4

This comprehensive peer-reviewed set of more than 600 definitions covers topics of interest for the biopharmaceutical and gene therapy subjects of genetics, therapeutics, drug development, clinical medicine, and the analytical science tools used for characterization of drugs. This glossary serves as a helpful reference to both novice and advanced scientists, engineers, and business executives involved with biopharmaceuticals and gene therapy technologies. Online sources of information for topics covered in this guide are also included for additional insights.

12